Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tunlametinib+PD-1 mAb · 1 trial · 1 indication
Objective response rate is defined as the proportion of participants who achieve a best overall response of either complete response (CR) or partial response (PR) according to irRECIST (immune-related Response Evaluation Criteria in Solid Tumors) criteria.
| Arm | Type | Description |
|---|---|---|
| DTP | EXPERIMENTAL | Disitamab vedotin (RC48): 2.5 mg/kg intravenously on Day 1 of each 14-day cycle Tislelizumab: 400 mg intravenously on Day 1 of each 42-day cycle Tunlametinib: Orally every 12 hours at the dose determined during the safety run-in phase |
| Name | Type | Description |
|---|---|---|
| Tunlametinib+PD-1 mAb | DRUG | Disitamab vedotin (RC48): 2.5 mg/kg intravenously on Day 1 of each 14-day cycle Tislelizumab: 400 mg intravenously on Day 1 of each 42-day cycle Tunlametinib: Orally every 12 hours at the dose determined during the safety run-in phase |
Inclusion Criteria: Patients with advanced gastric cancer who have received at least two lines of prior systemic therapy or are intolerant to standard therapy; HER2 immunohistochemistry (IHC) 2+ or 3+; Presence of measurable target lesions according to irRECIST criteria; Expected survival of at lea...
Tunlametinib+PD-1 mAb is an investigational combination therapy being studied for the treatment of gastric adenocarcinoma. It is currently in Phase 2 clinical development. The combination is being evaluated in a clinical trial for advanced gastric cancer, specifically in patients with gastric adenocarcinoma.
Tunlametinib is a small molecule that targets MEK, a protein in the RAS-RAF-MEK-ERK signaling pathway. The PD-1 mAb component targets programmed cell death protein 1 (PD-1), an immune checkpoint receptor. Together, they are designed to inhibit tumor growth and enhance the immune response against cancer cells.
Tunlametinib+PD-1 mAb is being developed by BeOne Medicines Ltd., a biopharmaceutical company. The company's stock ticker is ONC. BeOne Medicines is conducting the Phase 2 clinical trial for this combination therapy in gastric adenocarcinoma.
Tunlametinib+PD-1 mAb is in Phase 2 clinical development. It is an investigational therapy, meaning it has not been approved by regulatory authorities. The drug is currently being studied in a Phase 2 trial for gastric adenocarcinoma, and its safety and efficacy are still being evaluated.
Tunlametinib+PD-1 mAb is being studied in a Phase 2 clinical trial with the identifier NCT07507526. The trial is titled 'A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer' and is expected to enroll 76 participants in China. The trial is not yet recruiting.
No, Tunlametinib+PD-1 mAb is not the same as Disitamab Vedotin. They are separate drugs being studied in combination in the same clinical trial. The trial NCT07507526 evaluates the combination of Disitamab Vedotin, Tunlametinib, and a PD-1 antibody for advanced gastric cancer.